News

NVIDIA Outlook Optimistic as Analysts Predict Robust Growth

NVIDIA Outlook Optimistic as Analysts Predict Robust Growth

NVIDIA’s Potential Growth Sparked by H20 GPU Approval

BofA Securities analyst Vivek Arya recently reiterated a Buy rating for NVIDIA Corp (NASDAQ: NVDA), setting a price target of $220. This bullish outlook comes ahead of NVIDIA's anticipated second-quarter earnings, underscored by sustained momentum in sales and solid long-term earnings projections.

Anticipated Revenue Surge for NVIDIA

Arya's forecast indicates that NVIDIA could generate second-quarter revenues around $47 billion, surpassing both the $45.8 billion consensus and NVIDIA's self-imposed $45 billion guidance. This revenue growth is attributed to strong performance in Blackwell GPUs and substantial investments in cloud infrastructure.

10% Potential Revenue Increase in Q3

For the third quarter, Arya predicts mid-teens sequential growth to approximately $54 billion, which also exceeds the consensus estimate of $52.5 billion. There’s further upside potential to $57–$60 billion if shipments for the H20 GPUs are allowed to recommence.

Rising Gross Margins and Long-Term Predictions

Gross margins are expected to elevate to 73%–74% by the third quarter, propelled by NVIDIA's robust rack-scale architecture. If the previously written-down H20 inventory valued at approximately $5.5 billion is utilized, margins could see a boost of 200–300 basis points. Arya has also adjusted sales forecasts for fiscal year 2026 (calendar 2025) to a range of $210–$215 billion, with anticipated pro forma EPS climbing to $4.70–$4.80, which is above the consensus of $4.38.

Impact of AI Investments on NVIDIA’s Performance

Arya's projections reflect consistent strength in NVIDIA’s Blackwell and Blackwell Ultra series, stemming from increasing AI-related capital expenditures by key hyperscalers like Alphabet's Google, Meta Platforms, Oracle, and xAI. This diversified clientele hints at a solid upcoming product pipeline, which should enhance profitability while opening doors for potential sales of $5–$10 billion from resumed H20 sales in the latter half of the year.

Challenges Ahead: Regulatory Risks and Competition

While optimism persists around NVIDIA's growth, Arya cautions about potential regulatory challenges affecting H20 shipments due to anticipated security probes in China. Additionally, as local contenders advance, the competitive landscape could shift, necessitating strict adherence to U.S. licensing regarding the shipment of 1-nm or 2-nm chips to maintain NVIDIA's competitive edge over rivals like Advanced Micro Devices.

Investment Trends Supporting Long-Term Growth

Recent robust capital expenditure forecasts from major U.S. hyperscalers bolster Arya's positive long-term perspective. For example, Meta has elevated its projected spend to $100 billion by calendar 2026, up from a previous estimate of $79 billion, signifying increased investment in server technologies. Financing these expansions, Microsoft noted that their spending is directly linked to secured contracts, aligning with overall trends benefiting NVIDIA.

Profit Projections Aligning with Market Growth

Reflecting on these market dynamics, Arya anticipates fiscal year 2027 (calendar 2026) earnings could hover around $7 per share, comparing favorably with a consensus of $5.87. Such growth assumes the total addressable market for AI accelerators expands significantly, projected to increase from $309 billion to $341 billion, proceeding at a 60% year-over-year growth rate. Consequently, NVIDIA could trade at 25 times forward earnings, consistent with its traditional P/E range.

Long-Term EPS Growth Potential

Looking further ahead, Arya suggests NVIDIA could target long-term EPS of $10 per share. He estimates that the company could capture about 10% of the global AI accelerator TAM, citing that NVIDIA has placed additional orders for 300,000 H20 GPU units with Taiwan Semiconductor Manufacturing Co (NYSE: TSM), along with previous orders of 600,000–700,000 units. If U.S. regulators approve these shipments, potential incremental sales from China could range from $6 to $10 billion, translating to an average selling price of around $10,000 per unit.

Investor Outlook on NVIDIA Performance

Despite the rosy expectations, Arya highlighted that some revenue might shift into the next year, with projections of $3–$4 billion potentially delayed due to supply chain ramp-up times. There are ongoing discussions among investors regarding the potential balance between H20 products, particularly concerning the yield challenges associated with standard Blackwell versus Blackwell Ultra series.

NVIDIA Stock Performance Snapshot

At the time of publication, NVIDIA shares have risen by 2.49%, trading at $178.05. This encourages optimism around NVIDIA's near-term outlook as it enters a phase of potential demand expansion driven by technological advancements and strategic market positioning.

Frequently Asked Questions

What is NVIDIA's current stock price?

NVIDIA's stock is trading at $178.05, showing a gain of 2.49% at the time of reporting.

What factors are influencing NVIDIA's revenue growth?

Strong sales of Blackwell GPUs and increasing demand from cloud infrastructure investments are key factors driving NVIDIA's revenue growth.

How do analysts predict NVIDIA's EPS growth?

Analysts project NVIDIA's earnings per share could approach $7 in fiscal 2027, with long-term targets around $10 per share.

What risks does NVIDIA face regarding the H20 GPU shipments?

NVIDIA could encounter regulatory risks connected to security checks in China, impacting H20 GPU sales and market competitiveness.

How are AI capital expenditures affecting NVIDIA's outlook?

Increased AI-related spending by major companies is enhancing NVIDIA's product pipeline and sales potential, particularly among hyperscalers.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Mynd.ai Alters ADS Ratio Affecting Share Dynamics

Updated Category News Views 82

Analyzing Mynd.ai's ADS Ratio Tweak When Mynd.ai decides to shake things up with the American Depositary Shares (ADS) ratio, it's like they're throwing a curveball straight at Wall Street. Listen up, this isn't just a deck shuffle—it's a fundamental tweak that could play a big role in the stock’s perceived value. Starting December 7, 2027, one ADS will leap from...

Continue Reading
Preventing Dental Issues in Kids: Valuable Tips Shared

Updated Category News Views 63

Pediatric Dental Challenges Under the Microscope When it comes to kids and dental health, we're talking about the fundamentals—the kind that sticks around and makes a difference in their future pearly whites. None of that flashy tech gizmo stuff, just straight-on strategies for resilient chompers. Cavities, gum irritation, early tooth alignment—these are the everyday...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 32

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
IRTC Faces Investigation: Shares Plunge Amid Uncertainty

Updated Category News Views 48

Securities Trouble on the Horizon: IRTC Takes a Hit Wake up and adjust your seat, folks—iRhythm Technologies (NASDAQ:IRTC) is in the spotlight, and it ain't pretty. Shares nosedived over 30% in a single morning, stirring up quite the murky waters for shareholders. The trigger? A less-than-stellar third-quarter report. The Numbers Don't Lie—Or Do They? Management...

Continue Reading
Encore Boston Harbor Workers Triumph After 62-Day Strike

Updated Category News Views 227

Labor Standoff at Encore Boston Harbor Ends After a stormy 62 days on the picket lines, around 1,300 workers at Encore Boston Harbor finally find themselves back at their posts, carrying with them the spoils of hard-fought victory. This isn't just a paper contract; it's a banner for worker solidarity. These aren't your run-of-the-mill stock flips, folks; this fight was...

Continue Reading
Kestrel Group Faces Financial Hit Despite Revenue Growth

Updated Category News Views 153

Kestrel's Financial Rollercoaster Continues Here's the deal with Kestrel Group, folks. They just dropped their Q3 2026 financials, and it's a mixed bag. The top line's looking solid with total revenues hitting $4.8 million, riding high on a 203% jump in Program Services fee income. But dig a little deeper, and there's a $16.4 million net loss staring us in the face....

Continue Reading
Pigeon Unveils Green Innovations at CIIE 2026

Updated Category News Views 159

An International Celebration: Cultural Connections at CIIE Babies have a way of bringing the world together. Every culture has its own quirks and traditions, but the love for a newborn is common ground. Pigeon gets that, and they're putting it on full display at the China International Import Expo (CIIE) in Shanghai. It's their fourth run at this rodeo, and they’re not...

Continue Reading
UP Fintech Faces Class Action: Key Investor Impacts

Updated Category News Views 116

UP Fintech's Tumultuous Ride Ever watch a stock tumble and think, "Here we go again?" That's UP Fintech Holding Limited (NASDAQ:TIGR) right now. It's staring down the barrel of a securities fraud class action lawsuit, and trust me, it's messier than yesterday's lunch special. The stock's already gone through the wringer, dropping a hefty 25.34% after some nasty news from...

Continue Reading
JOYEE N01 Kicks Off Global Launch with African Orders

Updated Category News Views 62

A New Chapter for JOYEE N01 There's a moment in every company's life when it either steps boldly into the future or stumbles back into obscurity. For FAW Bestune, October 28, 2026, was one of those defining moments. On this day, they launched global mass production of the JOYEE N01 in Yancheng, China. And boy, did they pull out all the stops—you don't see this kind of...

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 63

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading

Top 5 Most Recently Viewed Articles

Future Innovations in Cartoning Machines Market from 2025 Onwards

Updated Category News Views 135

Understanding the Growth of Cartoning Machines Market As we navigate through the evolving landscape of packaging automation, the cartoning machines market demonstrates a noteworthy trajectory, poised to escalate significantly in the coming years. Currently valued at approximately USD 8.72 billion, research forecasts this market to rise to USD 13.58 billion by 2034. This...

Continue Reading
Summary of Annual Meeting Results for NB Private Equity Partners

Updated Category News Views 161

Overview of the Annual General Meeting Results The Annual General Meeting (AGM) for NB Private Equity Partners Limited has recently concluded, bringing forth significant updates. During the meeting, held for the Class A Shareholders, every resolution on the agenda was passed without any changes, highlighting a unified direction for the company. The resolutions included a...

Continue Reading
AltaPointe Health's iPad Initiative to Combat 911 Misuse

Updated Category News Views 383

Innovative iPad Pilot Program by AltaPointe Health AltaPointe Health has taken a remarkable step in refining how behavioral health crises are managed. In collaboration with MyCare Technologies, local police, and fire-rescue services, they have launched a new pilot program that focuses on reducing non-emergency 911 calls. This initiative is aimed specifically at improving...

Continue Reading
EBLM Urges Action Following Verdict in Daniel Penny Case

Updated Category News Views 93

EBLM Supports the Jury's Verdict Every Black Life Matters (EBLM) expresses its support for the jury's not guilty verdict regarding Daniel Penny, emphasizing the importance of protecting others during crises. EBLM believes that rather than punishing individuals for taking action in dangerous situations, the focus should be on addressing the deeper systemic issues that...

Continue Reading
Eden's Innovative Hormone Therapy Made Accessible via Telehealth

Updated Category News Views 359

Eden Expands Its Telehealth Services for Female Hormone Therapy Eden has recently launched an innovative telehealth offering that provides women with unprecedented access to hormone replacement therapy (HRT) options. With this development, eligible individuals can consult with licensed healthcare providers across most states in the U.S. to discuss treatment for hormonal...

Continue Reading